Eclipse Foundation showcases open source innovation at embedded world 2026; Releases 2025 IoT and Embedded Survey Report Akoya to Help Support Leading Philanthropic Organization with Spatial Phenotyping Capabilities
CODEX’s single-cell, multiplex imaging capabilities to be included in Chan Zuckerberg Initiative grantee toolkit to…
Akoya to Help Support Leading Philanthropic Organization with Spatial Phenotyping Capabilities
CODEX’s single-cell, multiplex imaging capabilities to be included in Chan Zuckerberg Initiative grantee toolkit to…
Intercept to Present at the Raymond James 2021 Human Health Innovation Conference
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company…
Intercept to Present at the Raymond James 2021 Human Health Innovation Conference
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company…
Kriya Therapeutics Strengthens Leadership Team with the Appointment of Dr. Ilise Lombardo as Chief Medical Officer
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., June 15, 2021 (GLOBE NEWSWIRE) — Kriya…
Kriya Therapeutics Strengthens Leadership Team with the Appointment of Dr. Ilise Lombardo as Chief Medical Officer
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., June 15, 2021 (GLOBE NEWSWIRE) — Kriya…
BetterLife Pharma to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
BetterLife Pharma to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ:…
GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ:…
Codiak BioSciences Expands Executive Leadership
– Sriram Sathyanarayanan, Ph.D. promoted to Chief Scientific Officer – – Konstantin Konstantinov, Ph.D. named…
Codiak BioSciences Expands Executive Leadership
– Sriram Sathyanarayanan, Ph.D. promoted to Chief Scientific Officer – – Konstantin Konstantinov, Ph.D. named…
PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression
Potential for FDA 505(b)(2) regulatory pathway approval and FDA Fast Track designation Advancing Ketamine and…
PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression
Potential for FDA 505(b)(2) regulatory pathway approval and FDA Fast Track designation Advancing Ketamine and…
Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer
Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) — – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the…
Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer
Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) — – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the…
Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage…
Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage…
Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage…
Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage…